Drug Trial Radar · NCT06239116
A Study of RM-718 in Healthy Subjects and Patients With MC4R Pathway Impairment
Last checked: Nov 20, 2026Latest source record: Oct 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
111
Actual
Start
Mar 5, 2024
Primary completion
May 7, 2027
Study completion Nov 1, 2028
Sponsor
- Lead sponsor
- Rhythm Pharmaceuticals, Inc.Industry
- Sponsor type
- Industry
- First posted
- Feb 2, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the safety, tolerability, and PK of RM-718 in healthy subjects with obesity and in patients with MC4R Pathway Impairment
Conditions
- Hypothalamic Obesity
- Prader-Willi Syndrome
- PWS
Interventions
Part A: RM-718 or placebo (matched to specific RM-718 dose cohort)Drug
Single ascending dose of RM-718 or placebo (matched to specific RM-718 Part A dose cohort)
Part B: RM-718 or placebo (matched to specific RM-718 dose cohort)Drug
Multiple ascending doses of RM-718 or placebo (matched to specific RM-718 Part B dose cohorts)
Part C: RM-718Drug
Multiple ascending doses of RM-718
Part D: RM-718Drug
Multiple ascending doses of RM-718
Primary outcomes
What the sponsor says the trial is designed to measure.
- Parts A, B, C, D: Safety and Tolerability Assessed by Number of Study Participants with Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)Time frame: From Day 1 through the Safety-Follow-up call (up to Day 43 for all Part A cohorts, up to Day 70 for all Part B cohorts, up to Day 140 for Part C cohort, up to Day 210 for Part D cohort)
Locations
7 sites in 1 country. Site status is shown where the registry gives one.
UAB Pediatric Endocrinology (Part C and Part D)
Birmingham, Alabama
Ann and Robert H. Lurie Children's Hospital of Chicago (Part C and Part D)
Chicago, Illinois
Boston Children's Hospital (Part C only)
Boston, Massachusetts
Brigham and Women's Hospital (Part C and Part D)
Boston, Massachusetts
Vanderbilt University Medical Center (Part C only)
Nashville, Tennessee
Worldwide Clinical Trials (Part A and Part B)
San Antonio, Texas
University of Utah Pediatric Endocrine Clinic (Part C and Part D)
Salt Lake City, Utah
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.